Ambrx Biopharma Inc ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $358.38 million
- Book Value:
- Revenue TTM:
- $5.24 million
- Operating Margin TTM:
- Gross Profit TTM:
- $7.46 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ambrx Biopharma Inc ADR had its IPO on 2021-06-18 under the ticker symbol AMAM.
The company operates in the Healthcare sector and Biotechnology industry. Ambrx Biopharma Inc ADR has a staff strength of 81 employees.
Shares of Ambrx Biopharma Inc ADR opened at $9.01 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $8.76 - $9.18, and closed at $8.92.
This is a -0.45% slip from the previous day's closing price.
A total volume of 280,315 shares were traded at the close of the day’s session.
In the last one week, shares of Ambrx Biopharma Inc ADR have increased by +2.88%.
Ambrx Biopharma Inc ADR's Key Ratios
Ambrx Biopharma Inc ADR has a market cap of $358.38 million, indicating a price to book ratio of 0.1116 and a price to sales ratio of 16.5982.
In the last 12-months Ambrx Biopharma Inc ADR’s revenue was $5.24 million with a gross profit of $7.46 million and an EBITDA of $-75638000. The EBITDA ratio measures Ambrx Biopharma Inc ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ambrx Biopharma Inc ADR’s operating margin was -1487.22% while its return on assets stood at -24.66% with a return of equity of -54.12%.
In Q2, Ambrx Biopharma Inc ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 43.3%.
Ambrx Biopharma Inc ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $6.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ambrx Biopharma Inc ADR’s profitability.
Ambrx Biopharma Inc ADR stock is trading at a EV to sales ratio of 0.223 and a EV to EBITDA ratio of 1.0092. Its price to sales ratio in the trailing 12-months stood at 16.5982.
Ambrx Biopharma Inc ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $180.87 million
- Total Liabilities
- $25.74 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ambrx Biopharma Inc ADR ended 2023 with $180.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $180.87 million while shareholder equity stood at $141.89 million.
Ambrx Biopharma Inc ADR ended 2023 with $0 in deferred long-term liabilities, $25.74 million in other current liabilities, 27000.00 in common stock, $-265121000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $65.64 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Ambrx Biopharma Inc ADR’s total current assets stands at $121.01 million while long-term investments were $18.83 million and short-term investments were $45.25 million. Its net receivables were $2.24 million compared to accounts payable of $5.70 million and inventory worth $0.
In 2023, Ambrx Biopharma Inc ADR's operating cash flow was $-32102000.00 while its capital expenditure stood at $451500.
Comparatively, Ambrx Biopharma Inc ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ambrx Biopharma Inc ADR stock is currently trading at $8.92 per share. It touched a 52-week high of $13.07 and a 52-week low of $13.07. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $5.72 and 200-day moving average was $2.74 The short ratio stood at 0.65 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 5946.6% are held by institutions.
Frequently Asked Questions About Ambrx Biopharma Inc ADR
Similar Industry Stocks (Biotechnology)
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.